U.S. markets closed

Nurix Therapeutics, Inc. (NRIX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
13.03+0.14 (+1.09%)
At close: 04:00PM EDT
13.68 +0.65 (+4.99%)
After hours: 05:29PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close12.89
Bid12.42 x 1100
Ask14.10 x 1100
Day's Range12.84 - 13.61
52 Week Range7.52 - 36.24
Avg. Volume422,206
Market Cap612.956M
Beta (5Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-3.05
Earnings DateOct 12, 2022 - Oct 17, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NRIX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Nurix Therapeutics, Inc.
    ITOS: What does Argus have to say about ITOS?ITEOS THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors

    SAN FRANCISCO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Edward C. Saltzman to its board of directors. Mr. Saltzman has over 30 years of drug strategic development experience in the biopharmaceutical and biotechnology industries, and currently serves as Head of Biotech Strategy at Lumanity Inc., a global pharmaceutical and biotechnology adv

  • Zacks

    Nurix Therapeutics, Inc. (NRIX) Moves to Buy: Rationale Behind the Upgrade

    Nurix Therapeutics, Inc. (NRIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • GlobeNewswire

    Nurix Therapeutics to Participate in Upcoming Investor Conferences

    SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in September: Wells Fargo Healthcare ConferenceFireside chat: Wednesday, September 7 at 3:45 – 4:15 p.m. ETBaird 2022 Global Healthcare Conference Fireside chat: Tuesday, September 13 at 10:50